Company intelligence / Profile preview
Septerna
South San Francisco, California, United Statessepterna.com ↗
- Ownership
- Public · SEPN
- Employees
- ~75
- Development stage
- Phase 1
01
Overview
Septerna’s lead program, an oral small molecule PTH1R agonist for hypoparathyroidism, entered Phase 1 but was discontinued after reversible bilirubin elevations were observed; non-clinical studies are ongoing to understand the mechanism. Early pharmacology signals were seen. Next-generation PTH1R agonists with distinct chemistry are advancing toward candidate selection by end of 2025. The company’s MRGPRX2 NAM program for mast cell diseases expects a Phase 1 trial initiation in late 2025. Other pipeline assets remain preclinical.
- Therapeutic areas
- Metabolic DisordersEndocrinologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Financials
- Market cap
- $2.2B
- Total revenue
- $46M
- Enterprise value
- $1.9B
Beyond the preview
Go deeper on Septerna.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Septerna.